Enlicitide decanoate (MK-0616)
CORALreef Outcomes: enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756)
Study title/design: CORALreef Outcomes: enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756) Trial NCT06008756/MK-0616-015 (Recruiting). Estimated primary completion: 29 November 2029. Estimated study completion: 29 November 2029. Aim To evaluate the efficacy of enlicitide decanoate (MK-0616) compared to placebo in increasing the time…
read more »
CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869)
Study title/design: CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869) Trial NCT05952869/MK-0616-017 (Active, not recruiting). Estimated primary completion: 28 April 2025. Estimated study completion: 28 April 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in…
read more »
CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456)
Study title/design: CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456) Trial NCT059528456/MK-0616-013 (Active, not recruiting). Estimated primary completion: 15 August 2025. Estimated study completion: 15 August 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with…
read more »
Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126)
Study title/design: Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126) Trial NCT05261126/MK-0616-008 (Completed) Aim To assess the efficacy and safety of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with hypercholesterolaemia Study design Phase 2b, randomised, double-blind, placebo-controlled study of oral MK-0616 6…
read more »
